Can Lyrica (pregabalin) cause speech issues in patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Lyrica (Pregabalin) Cause Speech Issues?

Yes, Lyrica (pregabalin) can cause speech issues, specifically speech disorder, which occurred in 1-3% of patients in clinical trials, with higher rates at the 600 mg/day dose. 1

Evidence from FDA Drug Labeling

The FDA-approved prescribing information for pregabalin explicitly lists speech disorder as an adverse reaction in controlled clinical trials:

  • In postherpetic neuralgia trials: Speech disorder occurred in 0% at 75 mg/day, 0% at 150 mg/day, 1% at 300 mg/day, and 3% at 600 mg/day (compared to 0% with placebo) 1

  • In partial-onset seizure trials: Speech disorder occurred in 1% at 150 mg/day, 2% at 300 mg/day, and 7% at 600 mg/day (compared to 1% with placebo) 1

Related Cognitive and Communication Effects

Beyond direct speech problems, pregabalin causes several related adverse effects that can impact communication:

  • "Thinking abnormal" (primarily difficulty with concentration/attention, but also includes cognition and language problems and slowed thinking): occurred in 2-8% of patients across various doses 1

  • Confusion: occurred in 2-7% of patients, particularly at higher doses 1

  • Amnesia: occurred in 2-5% of patients 1

Dose-Dependent Relationship

The incidence of speech issues increases with higher doses of pregabalin, demonstrating a clear dose-response relationship. The 600 mg/day dose shows the highest rates of speech disorder (3-7% depending on the condition being treated), compared to lower or absent rates at 150-300 mg/day. 1

Clinical Implications

  • Speech issues are a recognized adverse effect of pregabalin and should be discussed with patients before initiating therapy 1

  • If speech problems develop, consider dose reduction as the effect appears dose-dependent 1

  • These effects were generally classified as "mild" to "moderate" intensity in most patients who experienced them 1

  • Speech disorder was among the adverse reactions that led to discontinuation in approximately 1% of patients in controlled trials 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.